The Politics of Patents and Drugs in Brazil and Mexico: The Industrial Bases of Health Policies

Abstract

After introducing pharmaceutical patents in the 1990s, Brazil subsequently adjusted the patent system to ameliorate its effects on drug prices, while Mexico introduced measures that reinforce and intensify these effects. The different trajectories are due to the nature of the actors pushing for reform and the patterns of coalitional formation and political mobilization. In Brazil government demand for expensive, patented drugs made health-oriented patent reform a priority. The existence of an autonomous local pharmaceutical sector allowed the Ministry of Health to build a supportive coalition. In Mexico government demand made reforms less urgent, and transformations of the pharmaceutical sector allowed patent-holding firms to commandeer a reform project. The existence of indigenous pharmaceutical capacities can broaden the political coalitions underpinning health reforms.

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 55 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.